BRAF and lung carcinoid tumor: Targetable genomic alterations in the 8 genes (EGFR, KRAS, ALK, MET, ROS1, BRAF, RET, and NTRK; see the “Methods” section) were detected in 44.0% of patients with LUAD (1051/3115, Additional file 2: Tables S2-S9), 33% (5/15) of patients with LUASC carcinoma, 17% (4/24) of patients with LCLC, 5.3% (18/337) of patients with LUSC, and 0% (0/74) of patients with lung carcinoid tumors (n = 50 typical and n = 24 atypical, Fig. 1A).